ImmunityBio

IBRX

ATLANTA, GA – – (Globe Newswire – May 18, 2023) – – Holzer & Holzer, LLC is investigating whether ImmunityBio, Inc. (“ImmunityBio,” or the “Company”) (NASDAQ: IBRX) complied with federal securities laws.  On May 11, 2023, ImmunityBio disclosed that it received a complete response letter from the FDA on May 9, 2023. The letter indicates that the FDA has determined that it would not approve the Biologics License Application (“BLA”) for its product candidate, Anktiva™ (N-803), in its present form.  Following this news, the price of the Company’s stock dropped.

If you purchased ImmunityBio stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at  cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/immunitybio/ to discuss your legal rights.

Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information
View Representation Agreement
Submit Your Form

Submit Your Information

Name(Required)
Address
Shares Purchased(Required)
Date of Shares Purchased
Number of Shares Acquired
Acquisition Price Per Share
 
Shares Sold
Date of Shares Sold
Number of Shares Sold
Selling Price Per Share
 
By clicking on the button below, I am requesting Holzer & Holzer, LLC send me documents necessary to retain the firm.